T1	p 70 159	postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ]
T2	p 331 441	postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .
T3	p 450 578	Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin
T4	p 691 728	Two hundred and twenty-eight patients
T5	p 1373 1385	136 patients
T6	p 2085 2105	GG or GA genotypes .
T7	p 2165 2190	patients with AA genotype
T8	p 2527 2580	postoperative stage II and III rectal cancer patients
T9	i 18 42	CCND1 A870G polymorphism
T10	i 120 159	adjuvant concurrent chemoradiotherapy ]
T11	i 381 441	capecitabine-based postoperative chemoradiotherapy ( CRT ) .
T12	i 531 578	CRT of capecitabine with or without oxaliplatin
T13	i 747 799	concurrent capecitabine and radiotherapy ( Cap-CRT )
T14	i 837 901	capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .
T15	i 2145 2156	Cap-Oxa-CRT
T16	i 2338 2345	Cap-CRT
T17	i 2456 2467	CCND1 A870G
T18	i 2594 2665	adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .
T19	o 46 66	acute adverse events
T20	o 299 327	acute adverse events ( AEs )
T21	o 902 916	Adverse events
T22	o 946 1018	Common Terminology Criteria for Adverse Events , v. 3.0 ( CTCAE v3.0 ) .
T23	o 1213 1222	acute AEs
T24	o 1396 1408	severe AEs .
T25	o 1593 1614	severe AEs . Diarrhea
T26	o 1635 1637	AE
T27	o 1644 1659	severe diarrhea
T28	o 1877 1894	severe diarrhea .
T29	o 1975 1990	severe diarrhea
T30	o 2229 2244	severe diarrhea
T31	o 2398 2415	severe diarrhea .
T32	o 2514 2523	acute AEs